SecBot SecBot
PRESS-RELEASE ·Filed Mar 11, 2026

ARVN

Arvinas Inc.
NEUTRAL
Impact 5/10
Horizondays Processed8mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

Traders should monitor the March 18 data presentation for any signals of tolerability, target engagement, or dose-dependent degradation, which could de-risk ARV-102 and support valuation. Positive signals may catalyze near-term upside, especially given recent insider buying.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$13.48
T+0 close · Mar 11, 2026 · via day close
Latest settled
−42.88%
T+60 · $7.70
Vs SPY
−54.40%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 11 $13.48entry
  2. T+1 · 8mo ago −7.42%α −5.93% · $12.48
  3. T+5 · 8mo ago −19.21%α −17.03% · $10.89
  4. T+20 · 7mo ago −17.14%α −17.66% · $11.17
  5. T+60 · 6mo ago −42.88%α −54.40% · $7.70
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Arvinas announced that Phase 1 clinical trial data for its investigational Parkinson’s disease drug ARV-102 will be presented at the AD/PD™ 2026 conference. The data will include safety, pharmacokinetic, and pharmacodynamic results from multiple doses in Parkinson’s patients, with a planned Phase 1b trial in progressive supranuclear palsy (PSP) pending regulatory feedback.

Key Facts

  • ARV-102 is an oral PROTAC degrader targeting LRRK2, designed to cross the blood-brain barrier.
  • Phase 1 data on safety, PK, and PD will be presented at AD/PD™ 2026 on March 18, 2026.
  • Arvinas plans to initiate a Phase 1b trial in PSP patients in the first half of 2026, pending regulatory feedback.
  • No efficacy data or clinical outcomes were disclosed, only safety and pharmacological profiles.

Financial Impact

No immediate financial impact; data presentation may influence investor sentiment ahead of future trial milestones.

cash runwayR&D valuationmarket sentiment

Risk Factors

  • Phase 1 data may show limited target engagement or safety concerns, which could delay development.
  • No guarantee of regulatory approval to proceed with PSP trial.
  • High biotech development risk: clinical setbacks could significantly impact valuation.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3253623

Track record

21 reports on ARVN

Performance horizon

6 of 9 bullish or bearish reports moved the stock their way by T+1. Best: +28.62% at T+60 after the Feb 23, 2026 report. 9 of 9 went positive at some point.

Filters
  1. Nov 3, 202613d ago S-3 Bearish 5/10 Entry $7.42 to $6.55 Now $6.77 +8.76% ▲ +11.73% +7.32% vs SPY
  2. Nov 3, 202613d ago 8-K Bearish 5/10 No price data
  3. Nov 3, 202613d ago Press Release Neutral 4/10 Entry $7.09 to $7.42 Now $6.77 −4.51% ▲ +4.65% +3.00% vs SPY
  4. Sep 4, 202610w ago 144 Neutral 3/10 Entry $9.08 to $8.76 Now $6.77 −25.44% ▼ −3.52% −3.06% vs SPY
  5. Jun 22, 202621w ago 8-K Neutral 3/10 Entry $8.14 to $8.05 Now $6.77 −16.83% ▼ −1.11% −1.06% vs SPY
  6. Jun 2, 202623w ago 8-K Bearish 6/10 Entry $7.70 to $7.74 Now $6.77 +12.08% ▼ −0.52% −0.12% vs SPY
  7. May 12, 202626w ago 8-K Mixed 6/10 No price data
  8. May 12, 202626w ago 8-K Bullish 7/10 Entry $9.57 to $9.87 Now $6.77 −29.26% ▲ +3.13% +2.56% vs SPY
  9. May 12, 202626w ago Press Release Bearish 8/10 Entry $9.57 to $9.87 Now $6.77 +29.26% ▼ −3.13% −2.56% vs SPY
  10. May 8, 202627w ago 144 Neutral 2/10 Entry $9.66 to $9.57 Now $6.77 −29.92% ▼ −0.93% −0.80% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 26m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 11, 2026